Salofalk 1g/Actuation Rectal Foam
Authorisation PA0573/004/005 · Dr. Falk Pharma GmbH
- Licence holder
- Dr. Falk Pharma GmbH (all products →)
- Active substance
- Mesalazine
- Clinical trials
- 5 clinical trials →
- Dosage form
- Rectal foam
- Route of administration
- Rectal use
- ATC codes
- A07EC, A07EC02
- First authorised
- 09/01/2009
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Hybrid application (Article 10(3) of Directive No 2001/83/EC)
Mesalazine: supply and approvals
43 authorised products on the HPRA list contain Mesalazine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- 2 supply notices, e.g. Claversal Micropellets 1,5 g (5 Nov 2025 to 16 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 17 years (since 9 January 2009). The HPRA list marks it as marketed in Ireland.
Other medicines with Mesalazine in Ireland
42 other products on the HPRA list contain Mesalazine, from 9 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Asacolon 1000 mg Suppository | Tillotts Pharma GmbH | National authorisation (PA) | Marketed |
| Asacolon 1600 mg modified-release tablets | Tillotts Pharma GmbH | National authorisation (PA) | Marketed |
| Asacolon 400mg Gastro-Resistant Tablets | Tillotts Pharma GmbH | National authorisation (PA) | Marketed |
| Asacolon 500 mg Suppositories | Tillotts Pharma GmbH | National authorisation (PA) | Marketed |
| Asacolon 800mg Gastro-resistant Tablets | Tillotts Pharma GmbH | National authorisation (PA) | Marketed |
| Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | Takeda Pharmaceuticals International AG Ireland Branch | National authorisation (PA) | Marketed |
| Pentasa 1 g prolonged-release tablets | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
| Pentasa 10 mg/ml Rectal Suspension | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
| Pentasa 1g Suppositories | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
| Pentasa 500 mg prolonged-release tablets | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
| Pentasa Sachet 1g prolonged-release granules | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
| Pentasa Sachet 2g prolonged-release granules | Ferring Ireland Ltd | National authorisation (PA) | Marketed |
Other substances in ATC group A07EC
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 2 other active substances share the group A07EC with this product:
Sulfasalazine (3) · Olsalazine sodium (2)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Dr. Falk Pharma GmbH holds 18 products on the HPRA list, with 3 different active substances; 14 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.